Assessment of Medicaid Drug Price Reductions Promised by Trump Administration

<img alt="Pfizer CEO Albert Bourla joined President Trump at the White House last year on Sept. 30 to announce a voluntary agreement to reduce some prescription drug prices. One element aimed to lower prices in the taxpayer-funded Medicaid program, but the program is still being built, and details about which drugs will be discounted remain under wraps." src="https://npr.brightspotcdn.com/dims3/default/strip/false/crop/4478x3039+0+0/resize/4478x3039!/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2F16%2F49%2F1dea290940da98ac52fe0dd02f39%2Fgettyimages-2238336352.jpg" /><p>The Trump administration's efforts to lower drug prices included promised changes to Medicaid. However, it remains unclear which drugs will be affected, and each state must opt in to the program.</p><p>(Image credit: Win McNamee)</p><img src="https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=nx-s1-5971066" />